Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aytu BioScience, Inc.

2.18
-0.1100-4.80%
Post-market: 2.180.00000.00%17:24 EDT
Volume:97.00K
Turnover:214.94K
Market Cap:19.57M
PE:-2.62
High:2.36
Open:2.27
Low:2.17
Close:2.29
Loading ...

Aytu BioPharma Initiated at Buy by Lake Street

Dow Jones
·
01 Jul

Lake Street Initiates Aytu BioPharma at Buy With $8 Price Target

MT Newswires Live
·
01 Jul

Aytu BioPharma Initiated at Buy by Ascendiant Capital

Dow Jones
·
30 Jun

Aytu BioPharma initiated with a Buy at Ascendiant

TIPRANKS
·
30 Jun

Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior VP of Scientific Affairs to Lead EXXUA(TM) Launch

Reuters
·
25 Jun

Aytu BioPharma Expands Lending Agreement with Eclipse Ahead of Antidepressant EXXUA Commercial Launch

Reuters
·
23 Jun

Joshua R. Disbrow, CEO, Reports Acquisition of Aytu Biopharma Inc. Common Shares

Reuters
·
11 Jun

Aytu BioPharma Inc. Raises $16.6 Million in Upsized Public Offering, Bolstering Efforts to Launch First-in-Class Antidepressant EXXUA

Reuters
·
10 Jun

Aytu Biopharma Inc. Announces $14.4 Million Upsized Public Offering of Common Stock

Reuters
·
06 Jun

Aytu BioPharma Inc. Secures Exclusive Agreement to Commercialize EXXUA for MDD Treatment in the U.S

Reuters
·
06 Jun

Aytu Biopharma Inc. Conducted Annual Stockholders Meeting

Reuters
·
22 May

Aytu Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
15 May

Aytu Biopharma Reports 32% Increase in Q3 2025 Net Revenue, Achieves $4.0 Million Net Income and Adjusted EBITDA of $3.9 Million

Reuters
·
15 May

Aytu BioPharma Q3 EPS $0.21 Beats $(0.17) Estimate, Sales $18.45M Beat $13.74M Estimate

Benzinga
·
15 May

Aytu Biopharma Inc expected to post a loss of 17 cents a share - Earnings Preview

Reuters
·
13 May

Aytu Biopharma Inc expected to post a loss of 17 cents a share - Earnings Preview

Reuters
·
10 May

Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

ACCESS Newswire
·
22 Apr

Aytu BioPharma’s treatment of Marfan syndrome receives FDA orphan designation

TIPRANKS
·
15 Apr

Aytu BioPharma, Inc. (NASDAQ:AYTU) On The Verge Of Breaking Even

Simply Wall St.
·
08 Apr

Loss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Set To Breakeven

Simply Wall St.
·
15 Feb